Tom Branna, Editorial Director01.21.21
The US Food and Drug Administration last month invited Dr. Kalyanam Nagabhushanam, president R&D, Sabinsa Corporation, to make a presentation as part of the CDER Botanical Drug Seminar Series.
Nagabhushanam's presentation covered curcuminoids and other nutritional ingredients. He reviewed efficacy data, mechanistic considerations of pharmacological activity, metabolism, effects of nutrients on gut microbiome and vice versa, as well as methods employed to detect and deter intentional contaminations were discussed. FDA has not evaluated the presented safety and efficacy information.
Nagabhushanam obtained a PhD from Baylor, Texas in organic chemistry with a full-time Welch Foundation Fellowship followed by a two-year postdoctoral research with Prof. David Lightner before returning to India in 1979. He worked in India for 20 years, with stops at IPCL (now part of Reliance Petrochemicals), Ciba-Geigy (now Novartis) and later with SPIC Pharma where he was head of R&D and bulk drug divisions. He moved back to the US in 1999 to work with Sami-Sabinsa group. His expertise is in organic synthesis, natural products chemistry and screening of botanical extracts for novel pharmacological activities. He is an author/inventor in more than 100 papers/patents.
Nagabhushanam's presentation covered curcuminoids and other nutritional ingredients. He reviewed efficacy data, mechanistic considerations of pharmacological activity, metabolism, effects of nutrients on gut microbiome and vice versa, as well as methods employed to detect and deter intentional contaminations were discussed. FDA has not evaluated the presented safety and efficacy information.
Nagabhushanam obtained a PhD from Baylor, Texas in organic chemistry with a full-time Welch Foundation Fellowship followed by a two-year postdoctoral research with Prof. David Lightner before returning to India in 1979. He worked in India for 20 years, with stops at IPCL (now part of Reliance Petrochemicals), Ciba-Geigy (now Novartis) and later with SPIC Pharma where he was head of R&D and bulk drug divisions. He moved back to the US in 1999 to work with Sami-Sabinsa group. His expertise is in organic synthesis, natural products chemistry and screening of botanical extracts for novel pharmacological activities. He is an author/inventor in more than 100 papers/patents.
